PET-MRI (Positron Emission Tomogra… for Parkinson's (NCT07213219)
Imaging predicts impulse control risk
- Trial ID
- NCT07213219
- Official Title
- Exploration of the Reward System in Parkinson's Patients With Paradoxical Sleep Behavior Disorders: a Multimodal Imaging Study
- Goal
- Imaging predicts impulse control risk
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- University Hospital, Clermont-Ferrand
- Study Type
- INTERVENTIONAL
- Enrollment
- 44 participants
- Conditions
- Parkinson's Disease (PD)
- Interventions
- PET-MRI (Positron Emission Tomography - Magnetic Resonance Imaging).
Summary For Families
Goal: Find out whether people with Parkinson's who act out their dreams, a condition called rapid eye movement sleep behavior disorder, have different levels of D2 dopamine receptors in the brain's reward areas, which might help explain why some develop impulse control problems on dopamine treatments. Approach: Participants will have a combined positron emission tomography and magnetic resonance imaging brain scan that measures how many D2 dopamine receptors are available in reward-related regions, and researchers will compare those with and without the sleep behavior disorder. Eligibility: Adults 45 to 80 with idiopathic Parkinson's for at least 3 years who have been on dopaminergic treatment including levodopa for at least one year; people with existing impulse control problems, severe depression, major cognitive or motor problems, or contraindications to PET-MRI are excluded.
Locations
- CHU Clermont-Ferrand, Clermont-Ferrand,, Clermont-Ferrand, France
- CH Le Puy en Velay, Le Puy-en-Velay, France
- CHRU Lyon, Lyon, France
Frequently Asked Questions
- What is this trial testing?
- This trial is studying PET-MRI (Positron Emission Tomography - Magnetic Resonance Imaging).. Goal: Find out whether people with Parkinson's who act out their dreams, a condition called rapid eye movement sleep behavior disorder, have different levels of D2 dopamine receptors in the brain's reward areas, which might help explain why some develop impulse control problems on dopamine treatments. Approach: Participants will have a combined positron emission tomography and magnetic resonance imaging brain scan that measures how many D2 dopamine receptors are available in reward-related regions, and researchers will compare those with and without the sleep behavior disorder. Eligibility: Adults 45 to 80 with idiopathic Parkinson's for at least 3 years who have been on dopaminergic treatment including levodopa for at least one year; people with existing impulse control problems, severe depression, major cognitive or motor problems, or contraindications to PET-MRI are excluded.
- Who can participate?
- Participants must be between 45 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 3 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 8 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- There is no placebo group. Everyone receives an active treatment; the study compares one treatment against another.
- What procedures are involved in this trial?
- Based on the protocol, this trial involves: PET scan (minimally invasive); MRI scan (non-invasive). Confirm the full schedule with the study coordinator.